Navigation Links
BioDelivery Sciences Announces Confirmation of Final Formulation of BEMA Buprenorphine/Naloxone Based on Positive BNX-102 Study
Date:12/20/2011

RALEIGH, N.C., Dec. 20, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced results from its confirmatory study, BNX-102, assessing the pharmacokinetics of its BEMA Buprenorphine/Naloxone (BNX) formulation compared to Suboxone.  The results confirm the final formulation and provide the basis for moving forward into the pivotal comparative pharmacokinetic study versus Suboxone. 

(Logo:  http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

BNX is being developed for the treatment of opioid dependence and contains the same drug components, both buprenorphine and naloxone, as Suboxone, the only currently marketed formulation.

"The results of the BNX-102 study confirmed that the formulation and dose selection derived from our earlier BNX-101 study provide comparable exposure of both component drugs to the reference standard, Suboxone," stated Dr. Andrew Finn, Executive Vice President of Product Development.  "Matching each of the pharmacokinetic standards for a combination product such as Suboxone presents particular drug delivery challenges – and as a result, despite numerous attempts, Suboxone remains without generic competition nearly two years after losing its market exclusivity.  Given the significance of this opportunity and the unusual development requirements for products with an abuse deterrent component, we now want to take the prudent step of confirming our regulatory strategy with the FDA by meeting with them in the next 30 days, or at their earliest availability, prior to proceeding to our pivotal comparative pharmacokinetic study, BNX-103, immediately thereafter.  We expect this conservative approach creates the potential to significantly reduce any potential regulatory risk for BNX and is consistent with our previously stated strategy."

"The results from this study increase our enthusiasm regarding this opportunity," stated Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "Suboxone currently generates more than $1 billion in annual sales with virtually no competition, resulting in a substantial commercial opportunity for BDSI.  Building on the approval of our first BEMA product, ONSOLIS, we believe that BNX has the potential to  seize a significant share of this growing market, and we believe that the things we have learned from our BNX program create the potential for additional opportunities involving other combination products in the future."

About BNX-102

BNX-102 was designed to compare the pharmacokinetics of BEMA Buprenorphine/Naloxone (BNX) to the reference product, Suboxone tablets.  Healthy volunteers were administered both treatments in a cross-over design.  Plasma concentrations of both buprenorphine and naloxone were assessed at intervals.  The two primary parameters measured were peak plasma concentrations (Cmax) and the overall exposure, or amount of drug delivered over a specific time interval (AUC), for both buprenorphine and naloxone.  The study was not designed to demonstrate bioequivalence.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release, the presentation described herein and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the timing and results of additional clinical studies of BEMA Buprenorphine/Naloxone and the FDA's review of any subsequent NDA for this product) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.

 


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
7. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
8. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
9. BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
10. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
11. Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced ... financial results before the market opens on Thursday, July ... Therapeutics will host a teleconference on Thursday, July 27, ... accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  ...
(Date:7/17/2017)...  MedX Holdings, Inc., the manufacturer and global distributor ... equipment, today announced the national roll out of its ... gold standard for the treatment of low back injuries ... How it works: ... practice who prescribe the MedX Home Back Machine Program ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Creative Pharmacist ... to provide the Pharmacist eCare Plan to Computer-Rx pharmacies through the ... the ability to develop the Pharmacist eCare Plan, a shared document detailing a ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... the United States, today announced its partnership with financial technology company, Automated Transaction ... foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service devices and ...
(Date:7/25/2017)... , ... July 25, 2017 , ... SignatureCare Emergency Center ... the Austin, TX area 24 Hours a day. , The Emergency Room ... , “We’ve been open four months now and things are running smoothly,” said ...
(Date:7/24/2017)... ... ... SignatureCare Emergency Center is looking to award their 2017 Fall ... deserving student. Get your applications in now as the deadline is approaching fast. ... is a nursing student at Prairie View A&M University with a 3.45 GPA. Castillo ...
(Date:7/24/2017)... California (PRWEB) , ... July 24, 2017 , ... ... fire in Oakland, California effectively destroyed the construction site and threatened numerous homes ... a July 7th article on NBCLosAngeles.com. Los Angeles Area consulting firm ...
Breaking Medicine News(10 mins):